Sequence 8 from Patent US 20120302729

General Information


DRACP ID  DRACP01411

Peptide Name   Sequence 8 from Patent US 20120302729

Sequence  EVILVG

Sequence Length  6

UniProt ID  Q90ZS6  Q9LTX9  Q9STW6  Q02028  Q5R511  O35501  Q3ZCH0  P38647  P48721  P38646  Q07093  Q5ZM98  P22774  Q2S307  Q8I0H7  Q05931  Q3IUI0  Q6MB26  A0L4Z2  Q5ZJM3  Q32DZ9  Q3Z3Q4  Q8XED0  Q323M3  Q0TJH0   

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01411

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C29H52N6O9

Absent amino acids  ACDFHKMNPQRSTWY

Common amino acids  V

Mass  71814

Pl  3.85

Basic residues  0

Acidic residues  1

Hydrophobic residues  4

Net charge  -1

Boman Index  1205

Hydrophobicity  213.33

Aliphatic Index  226.67

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2012/0302729 A1

Patent Title  Anticancer anti-mortalin peptide antibody.

Other Iinformation  Granted Patent Family: 8s / 8ex; Family Jurisdictions: EP, US, WO, JP; Legal Status: Inactive; Application No: 201013514755; Filed:Dec 9, 2010; Published: Nov 29, 2012; Earliest Priority: Dec 10, 2009; Granted: Nov 19, 2013

Other Published ID  EP2511371A1  EP2511371A4 




DRACP is developed by Dr.Zheng's team.